Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non–small cell lung cancer (WJOG 5910L)

BACKGROUND: Bevacizumab, a humanized antibody to vascular endothelial growth factor (VEGF), shows clinical activity against human cancer, with its addition to standard chemotherapy having been found to improve outcome in patients with advanced nonsquamous non–small cell lung cancer (NSCLC). However,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Takeda, Masayuki, Okamoto, Isamu, Yamanaka, Takeharu, Nakagawa, Kazuhiko, Nakanishi, Yoichi
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2012
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3500214/
https://ncbi.nlm.nih.gov/pubmed/22849580
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-12-327
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados